XML 32 R22.htm IDEA: XBRL DOCUMENT v3.21.2
Patent and Technology License Agreements (Details) - USD ($)
 1 Months Ended 9 Months Ended
Jun. 30, 2021
Apr. 30, 2020
Jun. 30, 2021
Patent and Technology License Agreements (Details) [Line Items]      
Annual fee paid $ 90,000    
Annual minimum royalty payment     $ 100,000
Increasing annual royalties     25,000
Maximum aggregate annual royalties     150,000
Payable amount to NAT     $ 1,100,000
Description of license agreement     the Company paid annual maintenance fees of $45,000 and $30,000 in January 2021 and 2020, respectively. The annual maintenance fee increases by $15,000 per year up to a maximum of $90,000. Annual maintenance fees cease on the first sale of product. We also must pay up to an aggregate of $2.1 million in milestone payments, contingent on the achievement of various regulatory and commercial milestones. Under the terms of the license agreement, we also must pay a royalty of mid- to upper-single digit percentages of net sales, depending on the amount of annual sales, and subject to downward adjustment to lower- to mid-single digit percentages in the event there is no valid patent for the product in the United States at the time of sale. After the first sale of product, we will owe an annual minimum royalty payment of $100,000 that will increase annually by $25,000 for the duration of the term.
Agreement expiration date     Jan. 02, 2034
Options paid   $ 100,000  
Research and development expense     $ 5,000,000
Developmental milestone, description     NoveCite is obligated to pay Novellus up to $51,000,000 upon the achievement of various regulatory and developmental milestones. NoveCite also must pay a royalty equal to low double-digit percentages of net sales, commencing upon the sale of a licensed product. This royalty is subject to downward adjustment to an upper-single digit percentage of net sales in any country in the event of the expiration of the last valid patent claim or if no valid patent claim exists in that country. The royalty will end on the earlier of (i) the date on which a biosimilar product is first marketed, sold, or distributed in the applicable country or (ii) the 10-year anniversary of the date of expiration of the last-to-expire valid patent claim in that country. In the case of a country where no licensed patent ever exists, the royalty will end on the later of (i) the date of expiry of such licensed product’s regulatory exclusivity and (ii) the 10-year anniversary of the date of the first commercial sale of the licensed product in the applicable country. In addition, NoveCite will pay to Novellus an amount equal to a mid-twenties percentage of any sublicensee fees it receives. 
Revenue percentage 50.00%   50.00%
NoveCite [member]      
Patent and Technology License Agreements (Details) [Line Items]      
Research and development expense     $ 5,000,000
Outstanding equity 25.00%   25.00%
Percentage of outstanding equity     75.00%
Percentage of ownership additional shares     25.00%